紫杉烷化疗与抗雄激素药物作为转移性去势抵抗性前列腺癌一线治疗的比较
该回顾性队列研究基于美国退伍军人健康管理局数据库,纳入1445例转移性去势抵抗性前列腺癌患者,比较一线抗雄激素治疗(阿比特龙、恩扎卢胺)与紫杉烷化疗(多西他赛)的疗效。经多变量和倾向评分分析,两组总生存无显著差异,但化疗至停药时间更短、停药后无治疗间期更长。既往ADT持续时间可能有助于治疗选择。
要点
- 一线抗雄激素治疗与紫杉烷化疗的总生存无显著差异。
- 化疗至停药时间短于抗雄激素治疗,但停药后无治疗间期更长。
- 既往ADT持续时间可能辅助选择化疗或抗雄激素治疗。
核心结论
- 在调整关键预后因素后,一线紫杉烷化疗与抗雄激素治疗的总生存相似。
- 化疗至停药时间更短,但停药后无治疗间期更长。
- 既往ADT持续时间可能有助于选择化疗或抗雄激素治疗。
研究设计与样本
- 回顾性队列研究,基于美国退伍军人健康管理局数据库。
- 纳入2012年10月至2014年9月启动一线抗雄激素治疗或化疗的mCRPC患者。
- 共1445例可评估患者,其中1108例接受抗雄激素治疗,337例接受化疗(多西他赛)。
- 采用Cox比例风险模型和倾向评分分析,调整既往ADT持续时间和可用预后因素。
主要发现
- 多变量分析显示抗雄激素治疗与化疗的总生存无显著差异(HR 1.041,95%CI 0.853-1.270,P=0.694)。
- 倾向评分分析显示总生存无显著差异(HR 1.047,95%CI 0.861-1.273,P=0.644)。
- 化疗至停药时间短于抗雄激素治疗(HR 2.339,95%CI 1.969-2.779,P<0.001)。
- 抗雄激素治疗队列中,既往ADT持续时间高于中位数与更长总生存相关(HR 0.566,95%CI 0.464-0.690,P<0.001)和更长至停药时间相关(HR 0.831,95%CI 0.699-0.988,P=0.036),化疗队列无此关联。
- 化疗队列中既往ADT持续时间低于中位数与更高的PSA缓解率相关(61.5% vs 51.1%,P=0.024)。
临床怎么用
- 一线治疗选择可综合考虑既往ADT持续时间,以个体化选择化疗或抗雄激素治疗。
- 需向患者说明化疗至停药时间可能更短,但停药后无治疗间期可能更长。
局限性
- 回顾性研究设计,可能存在选择偏倚。
- 数据来源于美国退伍军人健康管理局数据库,结果外推需谨慎。
- 作者称结果为假设生成性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess treatment patterns and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy or antiandrogen therapy. PATIENTS AND METHODS: Patients initiating first-line antiandrogen therapy (abiraterone, enzalutamide) or chemotherapy (taxane) between October 2012 and September 2014 were retrospectively identified in the US Veterans Health Administration database. The impact of antiandrogen therapy vs chemotherapy on overall survival (OS) and time to discontinuation was assessed using Cox proportional hazard models, adjusting for prior androgen deprivation therapy (ADT) duration and available prognostic factors. RESULTS: Overall, 1445 patients were evaluable, of whom 1108 received antiandrogen therapy and 337 received chemotherapy (docetaxel). On multivariable analysis and propensity score analysis, the OS times for antiandrogen therapy vs chemotherapy were not significantly different (hazard ratio [HR] 1.041, 95% confidence interval (CI) 0.853-1.270, P = 0.694, and HR 1.047, 95% CI 0.861-1.273, P = 0.644, respectively). Time to discontinuation was shorter for chemotherapy vs antiandrogen therapy (HR 2.339, 95% CI 1.969-2.779; P < 0.001). Prior ADT duration above the median was associated with longer OS (HR 0.566, 95% CI 0.464-0.690; P < 0.001) and time to discontinuation (HR 0.831, 95% CI 0.699-0.988; P = 0.036) in the antiandrogen therapy cohort and not the chemotherapy cohort, while prior ADT duration below the median was associated with higher prostate specific antigen (PSA) response rate in the chemotherapy vs antiandrogen therapy cohort (61.5% vs 51.1%; P = 0.024). The treatment-free interval after discontinuation was longer after first-line chemotherapy vs antiandrogen therapy (mean 53 vs 39 days; P = 0.030). CONCLUSION: After adjusting for key prognostic factors in this large mCRPC dataset, the OS was similar for first-line chemotherapy vs antiandrogen therapy despite shorter time to discontinuation with chemotherapy and longer treatment-free interval after first-line chemotherapy. These hypothesis-generating data also suggest that duration of prior ADT may assist in the selection of patients for chemotherapy vs antiandrogen therapy.
引用
- Sonpavde G, Huang A, Wang L, et al. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. BJU Int. 2018. PMID: 29388324. doi:10.1111/bju.14152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。